Open AccessDaratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
Author(s) -
Spica Davide,
Junker Till,
Dickenmann Michael,
Schaub Stefan,
Steiger Jürg,
Rüfli Tanja,
Halter Jörg,
Hopfer Helmut,
Holbro Andreas,
Hirt-Minkowski Patricia
Publication year - 2019
Publication title -
case reports in nephrology and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.278
H-Index - 7
ISSN - 2296-9705
DOI - 10.1159/000503951
Subject(s) - case report
We report the effectiveness of daratumumab, a human IgGκ monoclonal antibody targeting CD38 on plasma cells, for therapy-refractory antibody-mediated rejection (AMR) due to blood group antibodies in a 59-year-old man who received a living ABO-incompatible kidney transplantation. Standard treatment options for AMR due to blood group antibodies including immunoadsorption, lymphocyte depletion with anti-human T-lymphocyte globulins, intravenous methylprednisolone pulses and eculizumab limited tissue injury, however failed to sufficiently suppress blood group antibody production. After administration of daratumumab as a rescue therapy, blood group antibody titers decreased and remained at low levels without further immunoadsorption and allowed kidney graft function to recover.